BSX

Over the past six months, Boston Scientific's stock (BSX) has experienced a notable decline. The stock was down approximately 13.79% over the past 30 days and a significant 47.79% over the past 12 months, with a 52-week range between $53.63 and $109.50. Recent events impacting the stock include Q1 CY2026 earnings exceeding market revenue expectations but with lowered Q2 CY2026 revenue guidance and full-year adjusted EPS guidance, multiple securities class action lawsuits alleging misleading statements about the growth in the U.S. electrophysiology business, and strong Q3 2025 results with net sales of $5.065 billion and adjusted EPS of $0.75.